Erythema multiforme after CoronaVac vaccination

N.T. Lopes,C.E.O. Pinilla,A.C. Gerbase
DOI: https://doi.org/10.1111/jdv.17495
2021-07-21
Journal of the European Academy of Dermatology and Venereology
Abstract:<p>In January 2021, SARS-CoV-2 vaccine, CoronaVac developed by Sinovac Life Sciences (Beijing, China) was approved for use in Brazil by its National Health Surveillance. It is an inactivated SARS-CoV-2 virus adsorbed on aluminum hydroxide and diluted in sodium chloride and phosphate-buffered saline.<sup>1</sup> Like other novel vaccines against COVID-19, it can induce cutaneous adverse reactions, generally mild.<sup>1</sup> Erythema multiforme (EM) is an acute and usually self-limited immune-mediated mucocutaneous disorder.<sup>2</sup> It's related to infections in 90% of cases - mainly herpes simplex virus (HSV) infections - and in 10% of cases, to drugs.<sup>2</sup> Unusually, it has also been documented following vaccination.<sup>3</sup> We report a case of EM after CoronaVac vaccination.</p>
dermatology
What problem does this paper attempt to address?